Fluvoxamine combined with lenvatinib enhances anti-hepatocellular carcinoma immunity by promoting M1 macrophage and T-cell infiltration.
Repurposing an antidepressant with a cancer drug remodels liver tumors' immune environment in lab models, warranting clinical testing given fluvoxamine's safety history.
Drug repurposing of fluvoxamine with lenvatinib remodels the HCC immune microenvironment toward M1/anti-tumor phenotype in preclinical models, offering a novel sigma-1 receptor-based combination strategy. Preclinical efficacy warrants early clinical investigation given fluvoxamine's established safety profile.
What the study was
- Study design
- Preclinical experimental study (in vivo murine models)
- Population
- Murine hepatocellular carcinoma models
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Scientific reports
Why it surfaced
Novel SSRI drug repurposing for HCC immune remodeling; high novelty; animal study only; triage_score capped at 5 per non-human rule but adjusted to 6 given novel drug repurposing dimension.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.